The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The firm said net product revenues fell 11 percent year over year in the fourth quarter.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The firm has also begun an initiative to reduce and deliver sustainable revenue growth for 2019 to compensate for commercial challenges in the US market.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.